Agreements reached under this partnership
- 1
The Company grants an exclusive license in the field of human pharmaceuticals, and the partner will lead development and commercialization.
- 2
The Company has the right to receive milestone payments and royalties based on progress in development and sales.
- 3
The Company has obtained the right to receive an allocation of Giovel shares based on progress in development by Giovel.
These are items that the documents state the two companies will work on. The lines above and below represent arrangements between the two companies.
The impact of this agreement on consolidated full-year results for the fiscal year ending December 2026 is currently expected to be limited. Multiple value-realization events are expected over the next several years, and the agreement is expected to contribute to enhanced corporate value over the medium to long term.
| Item | Details |
|---|---|
| Name of alliance partner | Lazarus Pharmaceuticals, LLC, Giathera Pharmaceuticals, Inc., Giovel Pharmaceuticals, Inc. |
| Alliance partner's business activities | Lazarus Pharmaceuticals, LLC is a U.S. pharmaceutical development company. Giathera Pharmaceuticals, Inc. and Giovel Pharmaceuticals, Inc. are portfolio companies under Lazarus Pharmaceuticals, LLC and are responsible for the development and commercialization of the respective compounds. |
| Alliance partner's location | Pennsylvania, United States (Lazarus Pharmaceuticals, LLC) |
| Details of the alliance | The Company grants an exclusive license in the field of human pharmaceuticals, and the partner will lead development and commercialization., The Company has the right to receive milestone payments and royalties based on progress in development and sales., The Company has obtained the right to receive an allocation of Giovel shares based on progress in development by Giovel. |
| Date of board resolution | 12 June 2026 |
| Contract Date | 12 June 2026 |
| Alliance start date | 12 June 2026 (efforts toward clinical development and commercialization commenced upon execution of this agreement) |
| Impact on Business Performance | The impact of this agreement on consolidated full-year results for the fiscal year ending December 2026 is currently expected to be limited. Multiple value-realization events are expected over the next several years, and the agreement is expected to contribute to enhanced corporate value over the medium to long term. |
Items this document does not state (15)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.To deploy the Company's drug discovery technologies externally and, through development and commercialization by external partners, accelerate the development of multiple programs, diversify revenue opportunities and enhance corporate value.